search
Back to results

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Primary Purpose

Encephalitis, Tick-Borne

Status
Completed
Phase
Phase 3
Locations
Poland
Study Type
Interventional
Intervention
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
Sponsored by
Pfizer
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Encephalitis, Tick-Borne

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Male and female subjects will be eligible for participation in this study if they:

  • Understand the nature of the study, agree to its provisions and provide written informed consent (assent if the subjects is under 18 years of age);
  • Provide the written informed consent of their parents / legal guardian (if the subject is under 18 years of age);
  • Are aged >= 16 years (from the 16th birthday) at screening;
  • Are clinically healthy, (i.e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial);
  • Have a negative pregnancy test result at the first medical examination (if female and capable of bearing children);
  • Agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children);
  • Agree to keep a Subject Diary.

Exclusion Criteria:

Subjects will be excluded from participation in this study if they:

  • Have a history of any previous tick-borne encephalitis (TBE) vaccination;
  • Have a history of TBE infection;
  • Have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese B-encephalitis);
  • Have a history of allergic reactions, in particular to one of the components of the vaccine;
  • Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions;
  • Have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages);
  • Have donated blood or plasma within 30 days of study entry;
  • Have received a blood transfusion or immunoglobulins within 30 days of study entry;
  • Are known to be HIV positive (an HIV test is not required specifically for the purpose of this study);
  • Are simultaneously participating in another clinical trial including administration of an investigational product;
  • Have participated in any other clinical study within six weeks prior to study entry;
  • Are pregnant or breastfeeding (if female);
  • Are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator.
  • Have received any other vaccination within two weeks prior to study entry.

Sites / Locations

  • Centrum Badan Farmakologii Klinicznej monipol
  • Niepubliczny ZOZ "Atarax" s.c.
  • Niepubliczny ZOZ "VITA"
  • "PANTAMED" Sp. z o.o.

Outcomes

Primary Outcome Measures

Immunogenicity: Seropositivity rate as determined by Enzyme-Linked Immunosorbent Assay (ELISA) and Neutralization test (NT) at Days 7, 14 and 21 after the second vaccination, in stratum A and B separately, and in the two age strata combined.

Secondary Outcome Measures

Full Information

First Posted
April 13, 2007
Last Updated
April 18, 2023
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00460486
Brief Title
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
Official Title
Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
September 2006 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to investigate the immunogenicity and safety of FSME-IMMUN 0.5 ml in two age strata (stratum A: 16 to 49 years, stratum B: > 50 years), with the first and second vaccinations being administered according to a rapid immunization schedule (12 ± 2 days apart). The third vaccination will be administered approximately 6 months after the first dose.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Encephalitis, Tick-Borne

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
330 (false)

8. Arms, Groups, and Interventions

Intervention Type
Biological
Intervention Name(s)
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
Primary Outcome Measure Information:
Title
Immunogenicity: Seropositivity rate as determined by Enzyme-Linked Immunosorbent Assay (ELISA) and Neutralization test (NT) at Days 7, 14 and 21 after the second vaccination, in stratum A and B separately, and in the two age strata combined.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and female subjects will be eligible for participation in this study if they: Understand the nature of the study, agree to its provisions and provide written informed consent (assent if the subjects is under 18 years of age); Provide the written informed consent of their parents / legal guardian (if the subject is under 18 years of age); Are aged >= 16 years (from the 16th birthday) at screening; Are clinically healthy, (i.e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial); Have a negative pregnancy test result at the first medical examination (if female and capable of bearing children); Agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children); Agree to keep a Subject Diary. Exclusion Criteria: Subjects will be excluded from participation in this study if they: Have a history of any previous tick-borne encephalitis (TBE) vaccination; Have a history of TBE infection; Have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese B-encephalitis); Have a history of allergic reactions, in particular to one of the components of the vaccine; Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions; Have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages); Have donated blood or plasma within 30 days of study entry; Have received a blood transfusion or immunoglobulins within 30 days of study entry; Are known to be HIV positive (an HIV test is not required specifically for the purpose of this study); Are simultaneously participating in another clinical trial including administration of an investigational product; Have participated in any other clinical study within six weeks prior to study entry; Are pregnant or breastfeeding (if female); Are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator. Have received any other vaccination within two weeks prior to study entry.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Baxter BioScience Investigator, MD
Organizational Affiliation
Baxter BioScience
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centrum Badan Farmakologii Klinicznej monipol
City
Krakow
ZIP/Postal Code
30-969
Country
Poland
Facility Name
Niepubliczny ZOZ "Atarax" s.c.
City
Olsztyn
ZIP/Postal Code
10-117
Country
Poland
Facility Name
Niepubliczny ZOZ "VITA"
City
Olsztyn
ZIP/Postal Code
10-295
Country
Poland
Facility Name
"PANTAMED" Sp. z o.o.
City
Olsztyn
ZIP/Postal Code
10-461
Country
Poland

12. IPD Sharing Statement

Learn more about this trial

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

We'll reach out to this number within 24 hrs